000			01877 a2200457 4500
005			20250516104643.0
264		0	_c20130502
008			201305s 0 0 ger d
022			_a1563-258X
024	7		_a10.1007/s10354-012-0106-z _2doi
040			_aNLM _beng _cNLM
100	1		_aKudlacek, Stefan
245	0	0	_a[Osteoporosis in men receiving androgen deprivation therapy for non-metastatic prostate cancer]. _h[electronic resource]
260			_bWiener medizinische Wochenschrift (1946) _cSep 2012
300			_a380-5 p. _bdigital
500			_aPublication Type: Case Reports; Comparative Study; English Abstract; Journal Article; Review
650	0	4	_aAged, 80 and over
650	0	4	_aAndrogen Antagonists _xadverse effects
650	0	4	_aAntibodies, Monoclonal, Humanized _xadverse effects
650	0	4	_aAntineoplastic Agents, Hormonal _xadverse effects
650	0	4	_aBone Density _xdrug effects
650	0	4	_aBone Density Conservation Agents _xadverse effects
650	0	4	_aDenosumab
650	0	4	_aDiphosphonates _xadverse effects
650	0	4	_aGonadotropin-Releasing Hormone _xagonists
650	0	4	_aHumans
650	0	4	_aMale
650	0	4	_aNeoplasm Staging
650	0	4	_aOsteoclasts _xdrug effects
650	0	4	_aOsteoporosis _xchemically induced
650	0	4	_aOsteoporotic Fractures _xchemically induced
650	0	4	_aProstatic Neoplasms _xdrug therapy
650	0	4	_aRANK Ligand _xantagonists & inhibitors
650	0	4	_aRandomized Controlled Trials as Topic
650	0	4	_aSelective Estrogen Receptor Modulators _xadverse effects
650	0	4	_aSpinal Fractures _xchemically induced
650	0	4	_aToremifene _xadverse effects
700	1		_aPuntus, Thomas
773	0		_tWiener medizinische Wochenschrift (1946) _gvol. 162 _gno. 17-18 _gp. 380-5
856	4	0	_uhttps://doi.org/10.1007/s10354-012-0106-z _zAvailable from publisher's website
999			_c22010029 _d22010029